FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marty St Clair

Research Profile

Living Beings

Chemicals & Drugs

Disorders

HIV Infections

Physiology

Procedures

Drug Therapy, Combination

Co-author Network

Publications

TOP 3
Richard J Hazen; Robert Harvey; Robert G Ferris; Charles Craig; Phillip Yates; Philip Griffin; John Miller; Istvan Kaldor; John Ray; Vicente Samano; Eric S Furfine; Andrew Spaltenstein; Michael Hale; Roger D Tung; Marty St Clair; Mary H Hanlon; Lawrence R Boone
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Lisa L Ross; Neil Parkin; Peter Gerondelis; Colombe Chappey; Mark Richard Underwood; Marty St Clair; E Randall Lanier
Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.
Matthew Bidwell Goetz; Monique R Ferguson; Xueliang Han; Greg McMillan; Marty St Clair; Keith A Pappa; Daniel R McClernon; William A O'Brien
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marty St Clair (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Richard J Hazen; Robert Harvey; Robert G Ferris; Charles Craig; Phillip Yates; Philip Griffin; John Miller; Istvan Kaldor; John Ray; Vicente Samano; Eric S Furfine; Andrew Spaltenstein; Michael Hale; Roger D Tung; Marty St Clair; Mary H Hanlon; Lawrence R Boone
In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
Antimicrobial agents and chemotherapy 2007;51(9):3147-54.
2006: Lisa L Ross; Neil Parkin; Peter Gerondelis; Colombe Chappey; Mark Richard Underwood; Marty St Clair; E Randall Lanier
Differential impact of thymidine analogue mutations on emtricitabine and lamivudine susceptibility.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):567-70.
2006: Matthew Bidwell Goetz; Monique R Ferguson; Xueliang Han; Greg McMillan; Marty St Clair; Keith A Pappa; Daniel R McClernon; William A O'Brien
Evolution of HIV resistance mutations in patients maintained on a stable treatment regimen after virologic failure.
Journal of acquired immune deficiency syndromes (1999) 2006;43(5):541-9.
2006: Daniel R McClernon; CL Vavro; Marty St Clair
Evaluation of a real-time nucleic acid sequence-based amplification assay using molecular beacons for detection of human immunodeficiency virus type 1.
Journal of clinical microbiology 2006;44(6):2280-2.
2006: P J Yates; Richard J Hazen; Marty St Clair; Lawrence R Boone; Margaret Tisdale; Robert Elston
In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
Antimicrobial agents and chemotherapy 2006;50(3):1092-5.
2005: Richard J Hazen; Robert J Harvey; Marty St Clair; Robert G Ferris; George A Freeman; Jeffrey H Tidwell; Lee T Schaller; Jill R Cowan; Steven A Short; Karen R Romines; Joseph H Chan; Lawrence R Boone
Anti-human immunodeficiency virus type 1 activity of the nonnucleoside reverse transcriptase inhibitor GW678248 in combination with other antiretrovirals against clinical isolate viruses and in vitro selection for resistance.
Antimicrobial agents and chemotherapy 2005;49(11):4465-73.
2005: Robert G Ferris; Richard J Hazen; Grace B Roberts; Marty St Clair; Joseph H Chan; Karen R Romines; George A Freeman; Jeffrey H Tidwell; Lee T Schaller; Jill R Cowan; Steven A Short; Kurt L Weaver; Dean W Selleseth; Kelly R Moniri; Lawrence R Boone
Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor.
Antimicrobial agents and chemotherapy 2005;49(10):4046-51.
2004: E Randall Lanier; N Givens; Chris Stone; Philip Griffin; Diana M Gibb; S Walker; Margaret Tisdale; David Irlbeck; M Underwood; Marty St Clair; Mounir Ait-Khaled
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
HIV medicine 2004;5(6):394-9.
2004: Joseph H Chan; George A Freeman; Jeffrey H Tidwell; Karen R Romines; Lee T Schaller; Jill R Cowan; Stephen S Gonzales; Gina S Lowell; C Webster Andrews; David J Reynolds; Marty St Clair; Richard J Hazen; Robert G Ferris; Katrina L Creech; Grace B Roberts; Steven A Short; Kurt Weaver; George W Koszalka; Lawrence R Boone
Novel benzophenones as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Journal of medicinal chemistry 2004;47(5):1175-82.
2004: E Randall Lanier; Mounir Ait-Khaled; Janna Scott; Chris Stone; Tom Melby; Glenn Sturge; Marty St Clair; Helen Steel; Seth Hetherington; Gillian Pearce; William Spreen; Steve Lafon
Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors.
Antiviral therapy 2004;9(1):37-45.
2003: Joel E Gallant; Peter Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard Haubrich; Marty St Clair; E Randall Lanier; Nicholas S Hellmann; Douglas D Richman
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.
Antiviral therapy 2003;8(6):489-506.
2001: A M Johnston; ME Valentine; Janet Ottinger; Ruth Baydo; Victoria E Gryszowka; CL Vavro; Kent J Weinhold; Marty St Clair; Ross E McKinney
Immune reconstitution in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy: a cohort study.
The Pediatric infectious disease journal 2001;20(10):941-6.
2001: Joseph H Chan; J S Hong; R N Hunter ; Gloria Faye Orr; Jill R Cowan; D B Sherman; S M Sparks; B E Reitter; C Webster Andrews; Richard J Hazen; Marty St Clair; Lawrence R Boone; Robert G Ferris; Katrina L Creech; Grace B Roberts; Steven A Short; Kurt Weaver; R J Ott; Jingshan Ren; A Hopkins; David I Stuart; David K Stammers
2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
Journal of medicinal chemistry 2001;44(12):1866-82.
2000: L Ross; M Johnson; R DeMasi; Q Liao; Neil Graham; M Shaefer; Marty St Clair
Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia.
AIDS (London, England) 2000;14(7):813-9.
2000: L Ross; M Johnson; Robert G Ferris; Steven A Short; Lawrence R Boone; Tom Melby; R Lanier; M Shaefer; Marty St Clair
Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy.
Journal of human virology 2000;3(3):144-9.
2000: Daniel R Kuritzkes; Anne Sevin; Benjamin Young; M Bakhtiari; H Wu; Marty St Clair; Elizabeth Connick; Alan Landay; John Spritzler; Harold Kessler; Michael M Lederman
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
The Journal of infectious diseases 2000;181(2):491-7.
2000: Elizabeth Connick; Michael M Lederman; Brian L Kotzin; John Spritzler; Daniel R Kuritzkes; Marty St Clair; Anne Sevin; Lawrence Fox; M H Chiozzi; JM Leonard; Franck Rousseau; J D'Arc Roe; Ana Martinez; Harold Kessler; Alan Landay
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
The Journal of infectious diseases 2000;181(1):358-63.
1999: Gregory T Spear; Gene Garrard Olinger; BL Sullivan; Alan L Landay; H Kessler; Elizabeth Connick; D Kuritzkes; Marty St Clair; John Spritzler; H Wu; M M Lederman
Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
AIDS research and human retroviruses 1999;15(18):1713-5.
1999: L Ross; CL Vavro; A Zimmermann; Marty St Clair
Rapid detection of the HIV type 1 reverse transcriptase codon T215Y by reverse transcription-polymerase chain reaction with fluorogenic probes.
AIDS research and human retroviruses 1999;15(14):1287-92.
1999: L Ross; M Johnson; Neil Graham; M Shaefer; Marty St Clair
The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Journal of human virology 1999;2(5):290-5.
1999: Jason W Chien; Hernan Valdez; Grace A McComsey; Daniel R McClernon; Marty St Clair; Michael M Lederman
Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients.
Journal of acquired immune deficiency syndromes (1999) 1999;21(4):277-80.
1999: AH Patki; SF Purvis; Hernan Valdez; John Spritzler; Elizabeth Connick; Daniel R Kuritzkes; Harold Kessler; Lawrence Fox; Marty St Clair; Alan Landay; Michael M Lederman
HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication.
AIDS (London, England) 1999;13(10):1177-85.
1998: Michael M Lederman; Elizabeth Connick; Alan Landay; Daniel R Kuritzkes; John Spritzler; Marty St Clair; Brian L Kotzin; Lawrence Fox; M H Chiozzi; JM Leonard; Franck Rousseau; M Wade; J D Roe; Ana Martinez; Harold Kessler
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
The Journal of infectious diseases 1998;178(1):70-9.
1998: ME Valentine; CR Jackson; CL Vavro; Catherine M Wilfert; Daniel R McClernon; Marty St Clair; Samuel L Katz; Ross E McKinney
Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients.
The Pediatric infectious disease journal 1998;17(1):18-23.
1997: justin charles mcarthur; Daniel R McClernon; M F Cronin; TE Nance-Sproson; Alfred J Saah; Marty St Clair; E Randall Lanier
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain.
Annals of neurology 1997;42(5):689-98.
1997: M B Faletto; Wayne H Miller; E P Garvey; Marty St Clair; S M Daluge; Steven S Good
Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89.
Antimicrobial agents and chemotherapy 1997;41(5):1099-107.
1997: S M Daluge; Steven S Good; M B Faletto; Wayne H Miller; Marty St Clair; Lawrence R Boone; M Tisdale; N R Parry; J E Reardon; Ronna E Dornsife; Devron Averett; T A Krenitsky
1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.
Antimicrobial agents and chemotherapy 1997;41(5):1082-93.
1997: CR Jackson; CL Vavro; ME Valentine; K N Pennington; E Randall Lanier; Samuel L Katz; JH Diliberti; Ross E McKinney; Catherine M Wilfert; Marty St Clair
Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus.
The Pediatric infectious disease journal 1997;16(2):200-4.
1996: Brendan Larder; A Kohli; Stuart Bloor; SD Kemp; P Richard Harrigan; Robert T Schooley; J M Lange; K N Pennington; Marty St Clair
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
Journal of virology 1996;70(9):5922-9.
1996: Robert T Schooley; C Ramirez-Ronda; J M Lange; D A Cooper; J Lavelle; L Lefkowitz; M Moore; Brendan Larder; Marty St Clair; J W Mulder; R McKinnis; K N Pennington; P Richard Harrigan; I Kinghorn; H Steel; J F Rooney
Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
The Journal of infectious diseases 1996;173(6):1354-66.
1996: J F Rooney; J C Warwick; M M Elkins; Marty St Clair; D W Barry
New initiatives in combination antiretroviral chemotherapy.
Advances in experimental medicine and biology 1996;394():373-82.
1996: Marty St Clair; J Millard; J Rooney; M Tisdale; N Parry; B M Sadler; M R Blum; G Painter
In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents.
Antiviral research 1996;29(1):53-6.
1995: Vasu Nair; Marty St Clair; J E Reardon; H C Krasny; R J Hazen; M T Paff; L R Boone; M Tisdale; I Najera; R E Dornsife
Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol.
Antimicrobial agents and chemotherapy 1995;39(9):1993-9.
1995: Marty St Clair; K N Pennington; J Rooney; D W Barry
Rapid screening of antiretroviral combinations.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10 Suppl 1():S24-7.
1995: Marty St Clair; K N Pennington; J Rooney; D W Barry
In vitro comparison of selected triple-drug combinations for suppression of HIV-1 replication: the Inter-Company Collaboration Protocol.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10 Suppl 2():S83-91.
1994: S M Daluge; D J Purifoy; P M Savina; Marty St Clair; N R Parry; I K Dev; P Novak; K M Ayers; J E Reardon; G B Roberts
5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.
Antimicrobial agents and chemotherapy 1994;38(7):1590-603.
1993: Marty St Clair; P M Hartigan; J C Andrews; CL Vavro; M S Simberkoff; J D Hamilton
Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group.
Journal of acquired immune deficiency syndromes 1993;6(8):891-7.
1993: C L Burns; Marty St Clair; L W Frick; Thomas Spector; Devron Averett; M L English; T J Holmes; T A Krenitsky; George W Koszalka
Novel 6-alkoxypurine 2',3'-dideoxynucleosides as inhibitors of the cytopathic effect of the human immunodeficiency virus.
Journal of medicinal chemistry 1993;36(3):378-84.
1992: Ray F Schinazi; A McMillan; D Cannon; R Mathis; R M Lloyd; A Peck; J P Sommadossi; Marty St Clair; J Wilson; P A Furman
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
Antimicrobial agents and chemotherapy 1992;36(11):2423-31.
1991: Marty St Clair; J L Martin; G Tudor-Williams; M C Bach; CL Vavro; D M King; Kellam Paul; SD Kemp; Brendan Larder
Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
Science (New York, N.Y.) 1991;253(5027):1557-9.
1991: R E Dornsife; Marty St Clair; A T Huang; T J Panella; George W Koszalka; C L Burns; Devron Averett
Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.
Antimicrobial agents and chemotherapy 1991;35(2):322-8.
1988: L W Frick; D J Nelson; Marty St Clair; P A Furman; T A Krenitsky
Effects of 3'-azido-3'-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cells.
Biochemical and biophysical research communications 1988;154(1):124-9.
1987: Marty St Clair; C A Richards; Thomas Spector; K J Weinhold; W H Miller; A J Langlois; P A Furman
3'-Azido-3'-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase.
Antimicrobial agents and chemotherapy 1987;31(12):1972-7.
1987: Marty St Clair; C U Lambe; P A Furman
Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information.
Antimicrobial agents and chemotherapy 1987;31(6):844-9.
1986: P A Furman; J A Fyfe; Marty St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(21):8333-7.
1985: H Mitsuya; K J Weinhold; P A Furman; Marty St Clair; S N Lehrman; Robert C Gallo; D Bolognesi; D W Barry; S Broder
3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(20):7096-100.
1985: Thomas Spector; Devron Averett; D J Nelson; C U Lambe; R W Morrison; Marty St Clair; P A Furman
Potentiation of antiherpetic activity of acyclovir by ribonucleotide reductase inhibition.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(12):4254-7.
1985: J D Hall; P A Furman; Marty St Clair; C W Knopf
Reduced in vivo mutagenesis by mutant herpes simplex DNA polymerase involves improved nucleotide selection.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(11):3889-93.
1984: P A Furman; Marty St Clair; Thomas Spector
Acyclovir triphosphate is a suicide inactivator of the herpes simplex virus DNA polymerase.
The Journal of biological chemistry 1984;259(15):9575-9.
1984: Marty St Clair; W H Miller; R L Miller; C U Lambe; P A Furman
Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U.
Antimicrobial agents and chemotherapy 1984;25(2):191-4.
1982: C D Sibrack; L T Gutman; C M Wilfert; C McLaren; Marty St Clair; P M Keller; D W Barry
Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child.
The Journal of infectious diseases 1982;146(5):673-82.
1982: D M Coen; P A Schaffer; P A Furman; P M Keller; Marty St Clair
Biochemical and genetic analysis of acyclovir-resistant mutants of herpes simplex virus type 1.
The American journal of medicine 1982;73(1A):351-60.
1981: P A Furman; D M Coen; Marty St Clair; P A Schaffer
Acyclovir-resistant mutants of herpes simplex virus type 1 express altered DNA polymerase or reduced acyclovir phosphorylating activities.
Journal of virology 1981;40(3):936-41.
1981: D Derse; Y C Cheng; P A Furman; Marty St Clair; GB Elion
Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function.
The Journal of biological chemistry 1981;256(22):11447-51.
1981: P A Furman; P de Miranda; Marty St Clair; GB Elion
Metabolism of acyclovir in virus-infected and uninfected cells.
Antimicrobial agents and chemotherapy 1981;20(4):518-24.
1980: Marty St Clair; P A Furman; C M Lubbers; GB Elion
Inhibition of cellular alpha and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir.
Antimicrobial agents and chemotherapy 1980;18(5):741-5.